drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody)
drug_description
An intravenous anti-CD38 IgG1 monoclonal antibody (Sarclisa) used as immunotherapy; mediates ADCC, CDC, and ADCP, induces direct apoptosis, and inhibits CD38 ectoenzyme (NADase) activity to reduce adenosine-mediated immunosuppression; targets CD38+ plasma and lymphoma cells and depletes CD38+ regulatory immune populations.
nci_thesaurus_concept_id
C90578
nci_thesaurus_preferred_term
Isatuximab
nci_thesaurus_definition
A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
drug_mesh_term
Isatuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Isatuximab is an anti-CD38 IgG1 monoclonal antibody that binds CD38 on malignant plasma cells and some lymphoma cells, mediating antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), and inducing direct apoptosis. It also inhibits CD38 ectoenzyme (NADase) activity, reducing adenosine-mediated immunosuppression and depleting CD38+ regulatory immune cells.
drug_name
Isatuximab
nct_id_drug_ref
NCT05346809